The renin angiotensin system blockade in kidney transplantation: pros and cons

@article{Cruzado2008TheRA,
  title={The renin angiotensin system blockade in kidney transplantation: pros and cons},
  author={Josep Mar{\'i}a Cruzado and Jorge Rico and Josep Maria Griny{\'o}},
  journal={Transplant International},
  year={2008},
  volume={21}
}
Besides the immunological mediated damage on the graft, the intrarenal renin‐angiotensin system (RAS) is viewed as an additional mechanism in the development and progression of chronic allograft injury. RAS blocking agents efficiently control post‐transplant hypertension and are useful to reduce proteinuria and for treating post‐transplant erythrocytosis. However, RAS blockade is associated with some potentially relevant adverse events as hyperkalemia, anemia, and even to a decline in renal… 
The renin-angiotensin system: an old, newly discovered player in immunoregulation.
Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions.
TLDR
An evidence-based approach to use of RAAS-inhibiting agents in kidney diseases is reviewed, a combination RAAS blockade treatment strategies are considered and some perspectives related to the implementation ofRAAS blockade in renal protection are discussed.
Hypertension in kidney transplant recipients
TLDR
Calcium channel blockers (CCB) and renin–angiotensin system (RAS) inhibitors are the most frequently used antihypertensive agents, but in many cases, a combination of these and other drugs is required to obtain good control of hypertension.
Angiotensin‐converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation
TLDR
Renin‐angiotensin system blockade retards the progression of diabetic and non‐diabetic chronic kidney disease of the native kidneys and has influence on morphologic and biochemical markers as well as on renal function, graft and patient survival after renal transplantation.
The Association Between Renin-Angiotensin System Blockade and Long-term Outcomes in Renal Transplant Recipients: The Wisconsin Allograft Recipient Database (WisARD)
TLDR
The findings suggest RAS blockade is associated with better patient and graft survival in renal transplant recipients and was associated with a 2-fold higher risk of hyperkalemia.
Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study.
  • D. Hernández, A. Muriel, A. Torres
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2012
TLDR
ACEI/ARB prescription may be suggested as beneficial among multiple medications for reducing mortality in kidney transplant recipients, but its use was not associated with longer graft survival.
Cardiovascular Death in Kidney Recipients Treated With Renin–Angiotensin System Blockers
TLDR
This large-scale retrospective analysis of prospectively collected data shows that the rate of cardiovascular death in kidney transplant recipients receiving ACEI/ARB or other antihypertensive medications is virtually identical.
Possible beneficial association between renin-angiotensin-aldosterone-system blockade usage and graft prognosis in allograft IgA nephropathy: a retrospective cohort study
TLDR
RAASB may be beneficial for graft prognosis in early allograft IgAN patients who require single antihypertensive medication therapy, by means of reducing albuminuria.
...
1
2
3
4
...

References

SHOWING 1-10 OF 101 REFERENCES
Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
Renal Protective Effects of the Renin-Angiotensin-Aldosterone System Blockade: From Evidence-Based Approach to Perspectives
TLDR
An evidence-based approach on the use of RAAS-inhibiting agents in kidney diseases is reviewed, treatment strategies in different clinical situations are considered and some perspectives related to the implementation of the RAAS blockade in renal protection are discussed.
Renal Allograft Protection with Angiotensin II Type 1 Receptor Antagonists
  • L. Tylicki, B. Biedunkiewicz, B. Rutkowski
  • Medicine, Biology
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2007
TLDR
Losartan reduces urine excretion of proteins associated with tubular damage and graft fibrosis, and significantly decreased N‐acetyl‐β‐d‐glucosaminidase and alfa‐1 microglobulin excretion relative to placebo and carvedilol.
Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation.
  • R. Holgado, F. Anaya, D. del Castillo
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2001
TLDR
A progressive decrease in mean arterial pressure associated with a decrease in proteinuria was observed during long-term follow-up in renal transplant recipients of losartan and this drug could be decisive for the treatment and prevention of chronic allograft nephropathy.
ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.
Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy.
TLDR
Losartan significantly decreases the plasma levels of TGF-beta1, the most important fibrogenetic factor, in transplant patients with chronic allograft nephropathy.
Role of hypertension in chronic renal allograft dysfunction.
TLDR
The complex nature of post-transplant hypertension has made it difficult to discern if its occurrence is the cause or the consequence of chronic allograft dysfunction, and the possibility remains that the two processes are not mutually exclusive and coexist.
Role of hypertension in chronic renal allograft dysfunction.
TLDR
The complex nature of post-transplant hypertension has made it difficult to discern if its occurrence is the cause or the consequence of chronic allograft dysfunction, and the possibility remains that the two processes are not mutually exclusive and coexist.
Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism.
TLDR
At comparable levels of BP control, losartan but not lacidipine effectively protects animals from chronic allograft injury and allows long-term survival.
Effect of Angiotensin II Receptor Blocker on Plasma Levels of TGF-β1 and Interstitial Fibrosis in Hypertensive Kidney Transplant Patients
TLDR
The study demonstrates that ARB significantly decreases the plasma levels of TGF-β1, proteinuria and uric acid, which could play an important and decisive role in the treatment and prevention of chronic allograft nephropathy.
...
1
2
3
4
5
...